Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'
3 months ago
Pharma
FDA+
Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis
3 months ago
Cargo Therapeutics scraps R&D pipeline, axes bulk of workforce as it looks for an exit
3 months ago
People
Regenxbio shares new Duchenne gene therapy data ahead of big readout next year
3 months ago
Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win
3 months ago
Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets
3 months ago
Deals
Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug
3 months ago
Deals
CRISPR company Arbor raises $73.9M to test therapy in clinical trials
3 months ago
Financing
Startups
AstraZeneca reports Phase 3 success for rare disease drug at heart of Amolyt deal
3 months ago
Pharma
Incyte's stock sinks as pivotal skin disease data disappoint
3 months ago
Orca Bio's T cell therapy may help blood cancer patients avoid transplant issues
3 months ago
Cell/Gene Tx
George Church spinout developing genomically recoded organisms cuts most employees
3 months ago
People
Startups
AstraZeneca spotlights first-in-human data for B7-H4-targeting ADC in endometrial cancer
3 months ago
Avidity seeks to 'set the standard' as it heads to FDA with Duchenne drug
3 months ago
Pharma
Boston Pharma, building off MASH momentum, mulls an IPO ahead of Phase 3 trial
3 months ago
Pfizer terminates an early-stage STING agonist trial
3 months ago
Pharma
Amgen reports more Uplizna data in myasthenia gravis ahead of FDA filing
3 months ago
Pharma
#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatment
4 months ago
Ono licenses rare blood disease drug from Ionis for $280M upfront
4 months ago
Deals
Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B
4 months ago
Deals
Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug
4 months ago
Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer
4 months ago
Beam shares promising first clinical data on gene editing treatment for a lung and liver disease
4 months ago
Cell/Gene Tx
#AAD25: What you need to know from Amgen, Bristol Myers, J&J and more
4 months ago
Pharma
First page
Previous page
10
11
12
13
14
15
16
Next page
Last page